This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Why Acadia Healthcare (ACHC) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Evaluating Acadia Healthcare's (ACHC) Future View: Hold or Fold?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to capitalize on increasing patient days and bed capacity.
Are Options Traders Betting on a Big Move in Acadia Healthcare (ACHC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Acadia Healthcare (ACHC) stock based on the movements in the options market lately.
Here's Why Acadia Healthcare (ACHC) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Select Medical (SEM) Stock Down 6.6% Despite Q3 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) continues to expect adjusted EBITDA to be between $795 million and $825 million in 2023.
Pediatrix (MD) Q3 Earnings Miss on High Costs, Shares Down 12%
by Zacks Equity Research
Pediatrix's (MD) third-quarter results suffer from the decline in same-unit revenues attributable to patient volume. Management currently expects 2023 adjusted EBITDA to be within $200-$210 million.
Zacks.com featured highlights Textron, Patterson-UTI Energy, ALLETE, Teekay Tankers and Acadia Healthcare
by Zacks Equity Research
Textron, Patterson-UTI Energy, ALLETE, Teekay Tankers and Acadia Healthcare have been highlighted in this Screen of The Week article.
Acadia Healthcare (ACHC) Q3 Earnings Beat on Patient Volumes
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q3 results benefit from growth in patient days and revenue per patient day. Management forecasts adjusted EPS, excluding income from the PRF, of $3.33-$3.43 for 2023.
Why Acadia Healthcare (ACHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Low-Leverage Stocks to Buy as Inflation Fear Eases
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt as debt-free stock is almost impossible to find. You may buy TXT, PTEN, ALE, TNK and ACHC.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.
Tenet Healthcare (THC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Tenet (THC) delivered earnings and revenue surprises of 20% and 1%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Community Health (CYH) Stock Down 1.7% Since Q3 Earnings Release
by Zacks Equity Research
Community Health (CYH) expects net operating revenues in the range of $12,400-$12,500 million for 2023.
Universal Health (UHS) Q3 Earnings Beat on Adjusted Patient Days
by Zacks Equity Research
Universal Health (UHS) has a leftover repurchase capacity of around $580 million as of Sep 30, 2023.
Universal Health Services (UHS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 8.97% and 0.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q3 Earnings Beat on Commercial Growth, View Raised
by Zacks Equity Research
Centene (CNC) anticipates adjusted EPS to register a minimum of $6.60 this year.
HCA Healthcare (HCA) Lags Q3 Earnings Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of -1.51% and 2.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Does Acadia Healthcare (ACHC) Have the Potential to Rally 26.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.1% in Acadia Healthcare (ACHC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Humana (HUM) Boosts Healthcare Choices for MA Members in Denver
by Zacks Equity Research
Humana (HUM) enters into a deal with Denver Health to expand its local provider network across the Denver area as well as offer greater care access to its Medicare Advantage members of the region.
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
by Indrajit Bandyopadhyay
Amid volatility, undervalued companies with solid prospects cushion investors from market jitters, while their robust fundamentals ensure higher returns. ACHC, PGNY, EGRX and NRBO are four such stocks.
All You Need to Know About Acadia Healthcare (ACHC) Rating Upgrade to Buy
by Zacks Equity Research
Acadia Healthcare (ACHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Down -11.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Acadia Healthcare (ACHC)
by Zacks Equity Research
Acadia Healthcare (ACHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.